MedPath

Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)

Phase 3
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
Registration Number
NCT06696443
Lead Sponsor
Vertex Pharmaceuticals Incorporated
Brief Summary

The purpose of this study is to evaluate the long-term safety and tolerability of SUZ and long-term effectiveness of SUZ in treating pain associated with DPN.

Detailed Description

A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy

Recruitment & Eligibility

Status
ENROLLING_BY_INVITATION
Sex
All
Target Recruitment
300
Inclusion Criteria

• Completed the final visit in the Treatment Period (i.e., Week 12) and subsequent 7-day period (to allow for taper of blinded capsule study drug) in a parent study such as VX24-548-110 or VX24-548-111

Key

Exclusion Criteria
  • Any sensory abnormality (excluding DPN)
  • History of drug intolerance in a parent study that would pose an additional risk to the participant in the opinion of the investigator
  • Current participation in an investigational drug trial (other than a parent study)

Other protocol defined Inclusion/Exclusion criteria may apply.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Suzetrigine (SUZ)SuzetrigineParticipants will receive SUZ once daily (qd) up to 52 weeks.
Primary Outcome Measures
NameTimeMethod
Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)From Baseline up to Week 54
Secondary Outcome Measures
NameTimeMethod
Change From Baseline in Study 36-item Short-form Health Status (SF-36v2) Physical Component Summary (PCS) ScoreFrom Baseline up to Week 52
Change From Baseline in the Short form McGill Pain Questionnaire-2 (SF-MPQ-2) Total ScoreFrom Baseline up to Week 52

Trial Locations

Locations (61)

Pinnacle Research Group, LLC

🇺🇸

Anniston, Alabama, United States

AMR Daphne, AL

🇺🇸

Daphne, Alabama, United States

Scottsdale Clinical Trials

🇺🇸

Scottsdale, Arizona, United States

Neuro-Pain Medical Center

🇺🇸

Fresno, California, United States

Long Beach Research Institute

🇺🇸

Long Beach, California, United States

Angel City Research, Inc

🇺🇸

Los Angeles, California, United States

Empire Clinical Research

🇺🇸

Pomona, California, United States

Clinical Trials Research

🇺🇸

Sacramento, California, United States

Velocity Clinical Research, San Bernardino

🇺🇸

San Bernardino, California, United States

Pain Management and Injury Relief

🇺🇸

Thousand Oaks, California, United States

Scroll for more (51 remaining)
Pinnacle Research Group, LLC
🇺🇸Anniston, Alabama, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.